Dr. Ido D. Weiss is a distinguished leader in the field of immunology and translational research, renowned for his expertise in cancer research and innovative imaging techniques. With a robust academic background and extensive professional experience, Dr. Weiss has made significant contributions to the understanding and treatment of cancer.

Dr. Weiss earned his Ph.D. in Immunology from The Hebrew University of Jerusalem, where he focused on advancing knowledge in life sciences and biotechnology. His postdoctoral work at the National Institute of Allergy and Infectious Diseases (NIAID) further honed his expertise, particularly in T cell biology and the use of positron emission tomography (PET) imaging for cancer biomarker studies. During this period, he was involved in establishing various cancer models in mice, which provided critical insights into cancer progression and therapeutic targets.

In his role as Senior Director of Translational Research at OncoC4, Inc., Dr. Weiss has led groundbreaking projects in targeted therapies and precision medicine. He has independently designed and executed experiments involving PET imaging of cancer biomarkers, contributing to the early clinical development of novel drugs and personalized therapies. His work includes evaluating immunotherapy, drug efficacy, and gene deficiencies in cancer models, which has been instrumental in advancing targeted treatment strategies.

Dr. Weiss’s expertise extends to pharmaceutical sample management and contract research organization (CRO) management, where he has demonstrated strong leadership and strategic planning capabilities. His skills in cross-functional team leadership and collaborative work have driven successful outcomes in complex research environments.

Dr. Weiss is also a published author, with notable contributions to journals such as Oncotarget and the Journal of Nuclear Medicine. His research on CXCR4 expression in adrenocortical carcinoma and PET imaging of tenascin-C underscores his commitment to advancing cancer research and improving diagnostic methods.

Among his accolades, Dr. Weiss received the Bench-to-Bedside Grant from the NIH, recognizing his efforts in translating preclinical research into clinical trials. Fluent in both English and Hebrew, Dr. Weiss has also served as a Major (Reserve) in the Israeli Defense Force, where he commanded a battery of 40 soldiers and officers, showcasing his leadership and dedication.

Dr. Ido D. Weiss continues to be a pivotal figure in the field of immunology and translational research, driving innovation and excellence in cancer treatment and diagnostics. His dedication to scientific advancement and his leadership in research have positioned him as a respected expert and influential contributor to the field.

Character: Ido Weiss is known for his relentless dedication to advancing cancer research, consistently demonstrating integrity and resilience in the face of complex challenges. His commitment to scientific excellence and ethical standards sets him apart as a leader in his field.

Knowledge: Ido possesses extensive expertise in immunology and cancer research, with a deep understanding of cutting-edge techniques such as PET imaging and biomarker development. His academic and practical experience enables him to drive innovative solutions and advancements in targeted cancer therapies.

Strategic: Ido excels in devising and executing strategic research initiatives that bridge preclinical studies with clinical applications, ensuring that scientific discoveries translate into tangible patient benefits. His ability to integrate various scientific disciplines and align them with strategic goals enhances the effectiveness of research and development efforts.

Communication: Ido communicates complex scientific concepts with clarity and precision, effectively conveying his research findings to both technical and non-technical audiences. His collaborative approach fosters strong relationships with colleagues, stakeholders, and research partners, facilitating successful project outcomes and advancing the field of cancer research.